Full Press Release Details
BURLINGAME, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced oral and poster presentations of key preclinical data relating to certain of its drug development programs at the American Association of Cancer Research (AACR) Annual Meeting, April 16-20, 2016 in New Orleans.
Following are the specifics for Corvus’ two poster presentations:
Inhibition of Adenosine A2A Receptor (A2AR) by CPI-444 Enhances CD8+ T cell Killing of a HER-2/neu Expressing Murine Tumor
| Authored by Blake A. Scott 1 , Todd Armstrong 2 , Elizabeth M. Jaffee 2 |
| Affiliations: 1 Johns Hopkins University School of Medicine, Baltimore, MD; 2 Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Experimental and Molecular Therapeutics |
| Session Date/ Time: Sunday, Apr 17, 1:00 PM – 5:00 PM |
| Location: Morial Convention Center, Halls G-J, Poster Section 17, Poster Board 1 |
The Adenosine A2A Receptor Antagonist, CPI-444, Blocks Adenosine-Mediated T Cell Suppression and Exhibits Anti-Tumor Activity Alone and In Combination with Anti-PD-1 and Anti-PD-L1
| Authored by Stephen Willingham 1 , Po Y. Ho 1 , Robert Leone 2 , Emily Piccione 1 , Carmen Choy 1 , Andrew Hotson 1 , Joseph Buggy 1 , Jonathan Powell 2 , Richard Miller 1 |
| Affiliations: 1 Corvus Pharmaceuticals, Burlingame, Calif. ; 2 Sidney Kimmel Comprehensive Cancer Research Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Immunology |
| Session Date/ Time: Monday, Apr 18, 1:00 PM – 5:00 PM |
| Location: Morial Convention Center, Halls G-J, Poster Section 26, Poster Board 21 |
The following oral presentation will take place as follows:
Adenosine A2a Receptor (A2aR) Antagonist as a Means of Enhancing the Efficacy of Checkpoint Blockade and Adoptive T Cell Therapy
| Authored by Robert D. Leone, Judson M. Englert, Chih-Hsien Cheng, Jiayu Wen, Min-Hee Oh, Im-Hong Sun, Chirag Patel, Ian A. Bettencourt, Jonathan D. Powell |
| Affiliation: Sidney Kimmel Comprehensive Cancer Research Center Johns Hopkins University School of Medicine, Baltimore |
| Session Category: Immunology |
| Session Date/ Time: Tuesday, Apr 19, 4:20 PM – 4:35 PM |
| Location: Morial Convention Center, New Orleans Theater C |
To learn more about the Corvus pipeline visit http://www.corvuspharma.com/technology/.
ABOUT CORVUS PHARMACEUTICALS
Corvus Pharmaceuticals (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company focused on the development and commercialization of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. For more information, visit www.corvuspharma.com.
Contact Data
Chief Financial Officer
Julie Normart, W2O Group
Contact
With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.